title: Unusual structure-genotoxicity relationship in mouse lymphoma cells observed with a series of kinase inhibitors.
abstract: During development of a novel kinase inhibitor for an anti-inflammatory therapy at AstraZeneca UK, the lead compound was found to be potently active in the mouse lymphoma assay (MLA). This was not believed to be due to primary pharmacology because structural alert relationships and a negative Ames test indicated that the compound was unlikely to form DNA adducts. A number of investigations were performed to assess whether mammalian cell genotoxicity was inherent to the chemical series. The in vitro micronucleus assay (MN(vit)) combined with a semi-automated analysis system, was used as a high-throughput screen. A number of additional compounds were selected for testing, all with different substituents around a core isoquinolinone. These modifications did not affect the kinase and non-kinase selectivity of the compounds. Several of these compounds were positive in the MN(vit), however, two compounds were found to be negative and these were also confirmed to be negative in the MLA. It was considered possible that topoisomerase II or off-target kinase inhibition may have been responsible for the observed mammalian cell genotoxicity. The present investigations show how an iterative chemical design, along with genotoxicity screening by use of a semi-automated MN(vit), can identify and remove the genotoxic hazard from pharmaceutical projects at an early stage of development, and produce high-quality molecules suitable for further progression.
authors.affiliation: AstraZeneca, R&D Alderley Park, Macclesfield, Cheshire, UK. mick.fellows@astrazeneca.com
authors.forename: Michael D
authors.initials: MD
authors.lastname: Fellows
authors.forename: Tim
authors.initials: T
authors.lastname: Luker
authors.forename: Anne
authors.initials: A
authors.lastname: Cooper
authors.forename: Michael R
authors.initials: MR
authors.lastname: O'Donovan
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D008223:Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D051379:Mice; D015162:Micronucleus Tests; D009152:Mutagenicity Tests; D009153:Mutagens / Q000737:chemistry*; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000633:toxicity*; D013329:Structure-Activity Relationship
chemical_list: D009153:Mutagens; D047428:Protein Kinase Inhibitors